Aplaket (Ticlopidine) is generally considered relevant for easing symptoms in high-risk vascular conditions where managing the risk associated with harmful blood clot formation is appropriate. Its use is commonly applied to patients who cannot be treated with aspirin.

The medication is commonly used to help with managing the risk of serious vascular events, including thrombotic stroke, Transient Ischemic Attack (TIA), and Myocardial Infarction. It is also relevant for managing risk in clinical settings following the placement of coronary stents and is applied to manage symptoms of Peripheral Arterial Disease (PAD), particularly Intermittent Claudication.

“Its therapeutic focus is on secondary prevention, which assists in addressing risk for patients who have already experienced a vascular event or who face extremely high risk.”

This approach helps maintain a sense of stability when symptoms are more noticeable, assisting with functional stability, and contributes to improved comfort during symptomatic periods.

---

Quick Fact: Relief for Impaired Circulation
Symptom Category	Ischemic symptoms related to physical activity
Target Manifestation	Intermittent Claudication (walking pain/cramping)
Patient Benefit Focus	May assist with maintaining functional stability and comfort

Regulatory References

1. NIH MedlinePlus overview of Ticlopidine

Who Can and Cannot Use Aplaket? (Ticlopidine)

This section defines the official population eligibility and non-eligibility criteria for Aplaket, based strictly on government regulatory documents.

Contraindicated Populations (Must Not Use)

Aplaket is absolutely contraindicated for patients with the following conditions, as stated in regulatory labeling:

• Known Hypersensitivity to ticlopidine.
• Any pre-existing hematopoietic disorder (e.g., neutropenia or thrombocytopenia) or a past history of TTP (Thrombotic Thrombocytopenic Purpura).
• A hemostatic disorder or active pathological bleeding (e.g., severe peptic ulcer bleeding or intracranial hemorrhage).
• Severe liver impairment.
• Patients who are pregnant or breastfeeding.

Eligibility and Restriction Rules

Category	Regulatory Status
Approved Population	Adult patients who have failed or are intolerant to aspirin therapy.
Pediatric Patients	Safety and effectiveness have not been established (use is not recommended).
Renal/Hepatic Function	Severe liver impairment is contraindicated. Renal impairment and mild-to-moderate hepatic impairment require caution due to limited experience.
Older Adults	Clearance is known to decrease with age, but no specific differences in side effects have been established.

Aplaket Interactions with other medicines and products

Official regulatory documents define the interaction profile of Aplaket (Ticlopidine) by focusing on pharmacodynamic risk, metabolic inhibition, and altered drug exposure.

---

Pharmacodynamic Interactions

Co-administration with other antiplatelet agents, Aspirin, or NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) is officially documented to potentiate the antiplatelet effect, which significantly increases the risk of bleeding. Similarly, using Aplaket with Anticoagulants (such as Heparin or Warfarin) is associated with an increased risk of hemorrhagic complications.

Metabolic and Exposure-Altering Interactions

Aplaket is documented as an inhibitor of specific liver enzymes, notably CYP2C19 and CYP2B6. This inhibition can lead to reduced clearance and resulting elevated plasma levels of certain co-administered medicines, including Theophylline and Phenytoin. Conversely, Ticlopidine co-administration causes a slight decrease in Digoxin plasma levels.

Administration of the H2-receptor antagonist Cimetidine reduces Ticlopidine clearance by 50%. The use of Antacids results in a reduction of Ticlopidine plasma concentrations, while taking the medicine with food increases the systemic exposure (absorption) of Ticlopidine.

Population and Restriction Notes

The clearance of Ticlopidine is officially noted to be reduced in patients with decreased hepatic function. Furthermore, trough plasma values are noted to be approximately twice as high in elderly patients compared to younger populations. Use is formally restricted and contraindicated in the presence of active pathological bleeding or hematopoietic disorders.

How Aplaket Works

The action of Aplaket (Ticlopidine) is governed by a highly specific, time-dependent mechanism that modifies platelet function at the molecular level. This purely pharmacodynamic mechanism is achieved through two main sequential domains of action.

P2Y12 Receptor Blockade and Irreversible Inhibition

The mechanism of Aplaket involves direct action on the P2Y12 receptor found on the surface of blood platelets. The medication is delivered as a prodrug that must first be converted into an active metabolite via hepatic metabolism. This metabolite acts as an irreversible inhibitor by forming a stable, covalent bond with the receptor. This interaction prevents ADP (Adenosine Diphosphate)—a key signaling molecule—from binding to and activating the platelet.

Attenuation of Platelet Signaling and Hemostatic Function

The irreversible P2Y12 blockade halts a crucial Gi-protein signaling cascade within the platelet. This molecular interruption prevents the full activation and conformational change of the Glycoprotein (GP) IIb/IIIa complex, which is the final common pathway responsible for linking platelets together via fibrinogen bridges. This mechanism produces the resulting physiological effect of impaired platelet aggregation and a measurable prolongation of bleeding time. The physiological result is an attenuated thrombus formation capacity within the vascular system. The time required for prodrug metabolism constrains the kinetics of the mechanism, resulting in a gradual onset of the maximum physiological effect over several days.

How to Use Aplaket

Aplaket is administered exclusively by the oral route as a 250 mg tablet.

---

Official Administration Regimen

Instruction	Detail
Route of administration	Oral (by mouth)
Dosing schedule	250 mg per dose, totaling 500 mg daily.
Timing in relation to meals	Must be taken with food or meals to aid proper absorption.
Frequency pattern	Twice a day (b.i.d.)

---

Procedural Conditions and Timecourse

The standard pattern of use involves the ingestion of one 250 mg tablet with food, administered two times each day. This frequency must be maintained consistently, as the full antiplatelet effect of the medication typically takes 8 to 11 days to be fully established. If administration is stopped, the antiplatelet function generally reverts to baseline levels within approximately one week.

Special Procedural Conditions

A crucial condition of use is the requirement for mandatory hematologic monitoring. This involves blood cell count and differential monitoring that must be conducted every two weeks for the first three months of therapy, commencing at the start of administration.

Population-Specific Rules

Regarding specific patient populations, the safety and effectiveness of the medicine have not been established for use in pediatric patients (under 18 years of age). For adult patients with moderate to severe hepatic or renal impairment, it is noted that a dose reduction or discontinuation may be necessary, though a specific, standardized adjustment schedule is not formally defined.

Research Evidence / Overview of Studies for Aplaket (Ticlopidine)

The research landscape for Aplaket, which contains the active ingredient Ticlopidine, includes large, controlled studies conducted over several decades. This overview describes the types of research that have explored its use, what the findings suggest when reviewed, and where limitations or gaps exist in the current body of evidence, according to official scientific and regulatory sources.

---

Evidence for Use in Secondary Prevention of Stroke and TIA

Research for this use was studied for adult patients who had recently experienced an ischemic stroke or a Transient Ischemic Attack (TIA), which are conditions associated with acute or disruptive episodes. The evidence base includes several large, international Randomized Controlled Trials (RCTs). The studies examined Ticlopidine against an inactive substance or other specific antiplatelet regimens used at the time of the research.

Studies monitored and tracked event rates for composite vascular outcomes, which combined the first occurrence of serious events like nonfatal stroke, nonfatal heart attack (myocardial infarction), and death from vascular causes. The research describes the event rates that were measured in the studied populations. These findings contribute to the broader evidence landscape for scientific review.

Evidence for Use in Peripheral Arterial Disease (PAD)

Ticlopidine was studied for its use in adult patients who have conditions marked by functional limitations, specifically Peripheral Arterial Disease (PAD) presenting as intermittent claudication (pain or cramping in the legs while walking).

Studies in this area research examined two types of outcomes: first, the rates of major systemic vascular events; and second, outcomes related to physical discomfort, such as changes in the distance patients could walk. Comparative evidence is lacking for Ticlopidine versus newer agents commonly used for PAD.

Research Gaps and Areas of Uncertainty

The evidence for Ticlopidine was observed in a context where the standard of care has since evolved. Comparative evidence is lacking from recent, large-scale trials against the antiplatelet agents that are now commonly used. Evidence quality varies across studies, and the interpretation of the older data was associated with the technological and pharmaceutical context of the time. Long-term effects are not fully established beyond the observation periods of the original RCTs.

Key Studies & References

1. Summary of Product Characteristics (SmPC) Ticlopidine Hydrochloride Tablets (Example regulatory reference for context)

Common questions about Aplaket (FAQ)

Q: How long after the first dose of Aplaket does its primary effect on platelets begin?

According to official documentation, the medicine is rapidly absorbed, with the highest concentration in the blood occurring around two hours after administration. This rapid absorption does not mean the full effect is immediate. The full antiplatelet effect, which is the main goal of treatment, is described as taking approximately 8 to 11 days to be fully established.

Q: What does the regulatory information state about taking Aplaket during pregnancy?

Official prescribing information states that Aplaket is contraindicated for use by patients who are pregnant or who may become pregnant. Pregnancy is explicitly listed as an absolute contraindication for use of this medicine.

Q: Is the use of Aplaket permitted while breastfeeding, according to official guidance?

Regulatory information indicates that discussion with a healthcare provider regarding the potential risks to the baby is recommended for patients who are breastfeeding. This step is defined to ensure a careful review of the situation against the official guidance.

Q: Is it common for a doctor to request a patient to stop Aplaket before surgery or dental work?

Official documentation indicates that the medicine may need to be temporarily stopped before certain surgeries or dental procedures to minimize bleeding risk. This discontinuation may occur approximately 10 days to 2 weeks prior to the procedure, and the final timing is always determined by a healthcare provider.

Q: How do the benefits of Aplaket generally compare to its risks, as described in regulatory summaries?

Regulatory summaries describe Aplaket as working to reduce the chance of harmful blood clots. This action, however, is also noted to increase the chance of serious bleeding in some people, which is the key safety concern defined in the official warnings.

Q: Is Aplaket the same type of medicine as aspirin?

No, official classifications indicate that Aplaket is an antiplatelet agent belonging to the synthetic thienopyridine derivative class. While aspirin is also used to affect platelets, it belongs to a different chemical class of medicine.

Q: Are there any signs of bleeding that are described as requiring immediate medical attention while taking Aplaket?

Official labeling describes several signs of serious bleeding which are listed as signs to monitor while taking this medicine. These include black, tarry, or bloody stools; vomiting blood; unexpected severe headache; or unusually heavy or unexpected menstrual bleeding.

Q: What is the general advice regarding alcohol consumption and Aplaket?

Regulatory-style consumer information includes a statement about limiting the consumption of alcoholic beverages while taking this medicine. This statement is part of the general precautions defined in the official documents.

Q: Is it necessary to stop taking Aplaket before having surgery or major dental work?

Official information states that treatment may have to be stopped about 10 days to 2 weeks prior to an operation or certain dental work. This temporary cessation is typically taken to minimize the risk of bleeding during the procedure and is managed by a healthcare provider.

Q: How is the clearance of Aplaket described in patients with renal impairment?

Official documentation notes that caution is required when the medicine is used in patients with renal impairment. Studies have examined the medicine in patients with chronic renal failure and demonstrated that a change in the recommended dosage was not indicated in those specific study groups.

Q: Can Aplaket be used in combination with aspirin, according to medical literature?

Official prescribing documents note that using this medicine in combination with aspirin potentiates, or increases, the antiplatelet effect. This combination is associated with an increased risk of bleeding and is described as necessitating medical consultation.

Q: How is the possibility of an allergic reaction to Aplaket described in official documents?

Official labeling lists signs of an allergic reaction that a patient may experience, which include rash, hives, itching, or swelling of the mouth, face, lips, tongue, or throat.

Q: What are the symptoms of a low white blood cell count associated with Aplaket use?

Regulatory labeling describes the risk of severe neutropenia, which is a reduction in white blood cells. The symptoms associated with this condition are described as signs of infection, such as fever, chills, flu-like symptoms, a very bad sore throat, or mouth sores.

Q: What is the advice if a person experiences heavy menstrual bleeding while taking Aplaket?

Unusually heavy or unexpected menstrual bleeding is specifically listed in the official safety information as a sign of serious bleeding. Official documentation describes this observation as requiring medical attention for review.

Q: Can Aplaket cause ringing in the ears (tinnitus)?

Official safety information lists ringing in the ears, known as tinnitus, as one of the less common adverse reactions reported in clinical trials for this medicine.

Q: What is the official guidance if a person misses a dose of Aplaket?

Official patient guidance describes a protocol for managing a missed dose. The general principle involves taking the missed dose if remembered promptly, or skipping the dose if the next scheduled time is near. The guidance strictly states that two doses should not be taken at once.

Q: Are there any specific restrictions on physical activities or contact sports while taking Aplaket?

Official patient guidance advises caution and notes that avoiding activities, such as contact sports, may be considered to mitigate the risk of injury, bruising, or bleeding while taking this medicine.

Q: Are there any specific forms of the medication (tablet, capsule, etc.) that Aplaket is available in?

The medicine is officially supplied as a 250 mg, white, oval, film-coated tablet that is taken orally. It is described as a single-ingredient product in this dosage form.

Q: Can Aplaket be used by patients who have a history of stomach ulcers?

Official safety warnings note that the chance of serious bleeding may be increased in patients who have a history of stomach ulcers. This increased risk is a point of caution detailed in the official documentation.

Q: What is the typical timeframe for follow-up appointments after starting Aplaket?

Official prescribing information establishes that hematologic monitoring, which involves checking blood cell counts, is required every two weeks for the first three months of therapy. This defined schedule sets the initial timeframe for necessary follow-up checks.

Storage Requirements

Aplaket (ticlopidine hydrochloride) tablets must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container and requires protection from both light and moisture. Temperatures outside the range of 15 C to 30 C (59 F to 86 F) are prohibited.

Handling and Disposal

For child safety, Aplaket must be stored out of the sight and reach of children. Regarding disposal, the product's official labeling states that special handling and disposal procedures should be followed, and any unused or expired product must be discarded in accordance with local requirements. Drug take-back programs are the preferred option for disposal.